Specific inhibition of macrophage TNF-α expression by in vivo ribozyme treatment

Kevin O. Kisich, Robert W. Malone, Paul A. Feldstein, Kent L Erickson

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

The overproduction of the cytokine TNF-α is associated with inflammatory and autoimmune diseases. We have developed a means to block TNF- α production with ribozymes directed against TNF-α mRNA to selectively inhibit its production in vitro and in vivo. Following cationic lipid- mediated delivery to peritoneal murine macrophages in culture, anti-TNF-α ribozymes were more effective inhibitors of TNF-α secretion than catalytically inactive ribozyme controls. Inhibition of TNF-α secretion was proportional to the concentration of ribozyme administered, with an IC50 of ~10 nM. After i.p. injection of cationic lipid/ribozyme complexes, elicited macrophages accumulated ~6% of the administered ribozyme. The catalytically active ribozyme suppressed LPS-stimulated TNF-α secretion by ~50% relative to an inactive ribozyme control without inhibiting secretion of another proinflammatory cytokine produced by macrophages, IL-1α. Ribozyme-specific TNF-α mRNA degradation products were found among the mRNA extracted from macrophages following in vivo ribozyme treatment and ex vivo stimulation. Thus, catalytic ribozymes can accumulate in appropriate target cells in vivo; once in the target cell, ribozymes can be potent inhibitors of specific gene expression.

Original languageEnglish (US)
Pages (from-to)2008-2016
Number of pages9
JournalJournal of Immunology
Volume163
Issue number4
StatePublished - Aug 15 1999

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Specific inhibition of macrophage TNF-α expression by in vivo ribozyme treatment'. Together they form a unique fingerprint.

  • Cite this